Treatment for hemophilia A consists of injecting the missing Factor VIII by I.V. to prevent or stop the bleeding. A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.
The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by a Bethesda test and is expressed in BU. 1BU neutralizes 50% of the activity of FVIII for hemophilia A.
Plasma with Factor VIII inhibitor can be used :
- As a plasma sample from a patient with hemophilia A with a Factor VIII inhibitor
- For accuracy control of Factor VIII inhibitor determination based on the Bethesda Test
- Title in Bethesda Unit depending on lots and tests
- 1 month stability after reconstitution
- 5 vials x 1 mL lyophilized plasma
